Yabing Guo

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1K citations

Hepatology, Bevacizumab Biosimilar, Medicine +8

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

Jian Zhou, Hui‐Chuan Sun, Zheng Wang et al. · Liver Cancer · 2023 · 389 citations · Full text

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

Rong Fan, George Papatheodoridis, Jian Sun et al. · Journal of Hepatology · 2020 · 323 citations · Full text

Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies

Zhanhui Wang, Jin Zhang, Hong Yang et al. · Journal of Medical Virology · 2003 · 168 citations

ACP risk grade: a simple mortality index for patients with confirmed or suspected severe acute respiratory syndrome coronavirus 2 disease (COVID-19) during the early stage of outbreak in Wuhan, China

Jiatao Lu, Shufang Hu, Rong Fan et al. · 2020 · 111 citations · Full text

Virus Epidemiology, Simple Mortality Index, Covid-19 Epidemiology +19